Doctors Note Logo

Published on: 9/16/2026

What are the most common side effects of Gemtesa?

The most commonly reported side effects of Gemtesa (vibegron), a beta-3 agonist used for overactive bladder, include headache, nasal congestion or sore throat, diarrhea, nausea, dry mouth, constipation, and urinary tract infection. Less common but more serious concerns involve difficulty emptying the bladder or urinary retention, which may be more likely in people with an enlarged prostate or those taking other bladder medications. Frequency, timing, and severity vary from person to person, and some reactions warrant prompt medical attention while others fade as your body adjusts. There are several important factors to consider, including drug interactions and warning signs to watch for, so see below to understand more.

Because bladder symptoms, medication reactions, and other conditions can look very similar, guessing can delay the care you need, and a free, instant, online symptom check can help you clarify what you are experiencing and decide on your next steps in just a few minutes.

Last reviewed for medical accuracy: 09/15/2025

answer background

Explanation

Gemtesa Side Effects: What You Need to Know

Gemtesa (vibegron) is a prescription medication used to treat overactive bladder (OAB) symptoms, such as frequent or urgent urination and urge urinary incontinence. Like all medicines, Gemtesa can cause side effects. Understanding the most common ones can help you recognize and manage them effectively. This guide summarizes reported side effects based on clinical trials and prescribing information, using clear, straightforward language.

Most Common Side Effects

Clinical studies of Gemtesa identified several adverse reactions occurring in at least 1% of patients and more often than with placebo. The most frequently reported side effects include:

  • Headache
    • Often mild to moderate in intensity
    • May occur within the first weeks of treatment
    • Usually resolves on its own; over-the-counter pain relievers can help

  • Urinary Tract Infection (UTI)
    • Symptoms include burning with urination, frequent urge to go, lower abdominal discomfort
    • Not necessarily caused by Gemtesa but reported more often in treated patients
    • May require antibiotic treatment—contact your doctor if you suspect a UTI

  • Nasopharyngitis (Common Cold)
    • Symptoms include runny or stuffy nose, sore throat, sneezing
    • Typically mild, lasting a few days
    • Rest, fluids, and over-the-counter cold remedies can provide relief

  • Diarrhea
    • Loose or watery stools
    • Usually temporary; maintain hydration and follow a bland diet (BRAT: bananas, rice, applesauce, toast)
    • Seek medical attention if diarrhea is severe or lasts more than 48 hours

  • Nausea
    • Mild queasiness or upset stomach
    • Taking Gemtesa with food may help reduce this effect
    • If nausea persists, talk to your doctor about management strategies

  • Constipation
    • Difficulty passing stools or infrequent bowel movements
    • Increase dietary fiber, fluids, and gentle exercise
    • Over-the-counter stool softeners may help—check with your healthcare provider first

What You Should Know

  1. Symptoms Vary by Person
    Everyone reacts differently to medications. While these side effects were the most common in trials, you may experience none, one, several, or others not listed here.

  2. Timing Matters
    Side effects often appear in the first few weeks of starting Gemtesa and may lessen with continued use. Keep track of how you feel and note when symptoms begin.

  3. Dose Adjustments
    If side effects become bothersome, your doctor may adjust the dose or suggest ways to manage them without stopping treatment.

  4. Drug Interactions
    Although Gemtesa has a low risk for many drug interactions, always inform your doctor about all prescription medicines, over-the-counter drugs, vitamins, and herbal supplements you take.

Tips for Managing Side Effects

  • Maintain good hydration to ease headaches, diarrhea, and UTIs.
  • Eat small, frequent meals if you feel nauseated.
  • Use a humidifier, saline nasal spray, or throat lozenges for cold-like symptoms.
  • Keep a symptom diary: note your side effects, their severity, and any triggers. This helps your healthcare provider tailor your care.
  • Never stop or change your dose without checking with your doctor.

When to Seek Medical Attention

While most side effects of Gemtesa are mild, you should contact your doctor right away if you experience:

  • Severe or persistent headache unrelieved by OTC painkillers
  • Signs of a serious UTI (fever, chills, back pain, blood in urine)
  • Intense abdominal pain with diarrhea lasting more than two days
  • Difficulty breathing, swelling of the face or throat (possible allergic reaction)
  • Sudden or worsening high blood pressure symptoms (severe headache, chest pain, vision changes)

If you believe you’re experiencing a life-threatening reaction, do not wait—seek emergency medical care immediately.

Free Symptom Check

Not sure if your symptoms are related to Gemtesa or something else? Consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to help you evaluate your next steps. free, online symptom check, using the doctor approved Ubie Symptom Checker

Talking with Your Doctor

Always discuss any new or worsening symptoms with your healthcare provider. Be honest about how you feel—this helps them make informed decisions about your treatment. If you’re concerned about serious side effects or life-threatening reactions, seek medical advice right away.

Remember: This information is meant to supplement—not replace—professional medical advice. Speak to a doctor about any side effect that worries you or if you think you’re having an emergency.

(References)

  • * Mitcheson HD, Samanta S, Muldowney K, Pinto CA, Rocha BA, Green S, Bennett N, Mudd PN Jr, Frenkl TL. Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial. Eur Urol. 2019 Feb;75(2):274-282. doi: 10.1016/j.eururo.2018.10.006. Epub 2018 Oct 25. PMID: 30661513.

  • * Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR. J Urol. 2020 Aug;204(2):316-324. doi: 10.1097/JU.0000000000000807. Epub 2020 Feb 18. PMID: 32068484.

  • * Vibegron (Gemtesa) for overactive bladder. Med Lett Drugs Ther. 2021 May 3;63(1623):67-69. PMID: 33976098.

  • * Kennelly MJ, Rhodes T, Girman CJ, Thomas E, Shortino D, Mudd PN Jr. Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison. Adv Ther. 2021 Nov;38(11):5452-5464. doi: 10.1007/s12325-021-01902-8. Epub 2021 Sep 18. PMID: 34537953; PMCID: PMC8520873.

  • * Drugs for benign prostatic hyperplasia. Med Lett Drugs Ther. 2022 May 2;64(1649):65-69. PMID: 35471226.

  • * He W, Zhang Y, Huang G, Tian Y, Sun Q, Liu X. Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta-analysis. Low Urin Tract Symptoms. 2023 May;15(3):80-88. doi: 10.1111/luts.12475. Epub 2023 Mar 2. PMID: 36863312.

  • * Drugs for overactive bladder. Med Lett Drugs Ther. 2023 Mar 20;65(1672):41-45. doi: 10.58347/tml.2023.1672a. PMID: 36897601.

  • * Staskin D, Owens-Grillo J, Thomas E, Rovner E, Cline K, Mujais S. Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial. J Urol. 2024 Aug;212(2):256-266. doi: 10.1097/JU.0000000000003999. Epub 2024 May 6. PMID: 38708869; PMCID: PMC12721610.

  • * Huang W, Zheng X, Luo J, Chen Y, Xu Y. Comparative efficacy and adverse effects of β3-agonists and antimuscarinics in overactive bladder: a network and component network meta-analysis. Eur J Clin Pharmacol. 2025 Aug;81(8):1217-1227. doi: 10.1007/s00228-025-03855-1. Epub 2025 Jun 7. PMID: 40483336.

  • * Yoshida M, Nishino Y, Nagae H, Kato S, Sakamoto S, Hojo M, Miyauchi T, Kageyama S, Takahashi S, Kuroda H, Mori N, Kasagi Y, Masunaga K, Nabeshima Y, Nomiya M, Iwashita K, Miyamae K, Otani M, Kawahara K, Ikeda M, Kubono S, Haga N. Efficacy and Safety of Vibegron Add-On Therapy for Persistent Overactive Bladder Symptoms in Benign Prostatic Hyperplasia Patients With α(1)-Blocker Treatment: A Multi-Center Prospective Randomized Controlled Study (VATON Study). Low Urin Tract Symptoms. 2026 Mar;18(2):e70053. doi: 10.1111/luts.70053. PMID: 41830191; PMCID: PMC12988341.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.